Finnish study tracks five year changes in Parkinson’s sleep symptoms

A five-year study led by researchers at Helsinki University Hospital and the University of Helsinki has revealed that sleep disturbances in Parkinson’s do not simply decline as a single, uniform package. Instead, different types of sleep difficulties evolve along distinct paths over time. While vivid dreaming, restless legs, and daytime drowsiness show a marked increase, traditional insomnia symptoms remain surprisingly stable. Researchers were tracking 183 people who provided complete data across a five-year interval, the team monitored how specific sleep patterns shifted as average time living with the condition rose from roughly five and a half years to nearly ten years. During this five-year window, total sleep duration barely budged, moving only slightly from an average of 7.0 hours to 7.2 hours a night. Similarly, standard insomnia complaints, such as trouble dropping off to sleep, waking up frequently during the night, waking too early in the morning, and feeling unrefreshed, did not experience significant worsening. Routine daytime fatigue and hallucinations also held steady across the study period. In sharp contrast, symptoms linked to rapid eye movement sleep, known as REM sleep, escalated considerably. The proportion of people talking in their sleep at least once a week jumped from 17.4 percent to 30.4 percent, while those dealing with weekly nightmares rose from 14.8 percent to 24.6 percent. Scores tracking symptoms of REM sleep behaviour disorder, where the brain’s natural muscle paralysis during dreams fails and causes physical movement, rose substantially, with about 40 percent crossing the screening threshold by year five compared to roughly 29 percent at the start. Daytime sleepiness and restless legs syndrome also showed noticeable progression. Daily napping grew from just over 21 percent to nearly 32 percent of participants, while those reporting excessive daytime drowsiness rose from 30.6 percent to 38.8 percent. Severe drowsiness almost doubled, affecting close to 15 percent by the end of the follow-up. Restless legs syndrome, which brings an irresistible urge to move the limbs in the evening or at night, climbed from 21 percent to just over 31 percent. When the researchers looked at what specifically influenced excessive daytime drowsiness, three distinct drivers stood out: symptoms of low mood, elevated risk of sleep apnoea, and the use of dopamine agonist medications. In fact, participants taking dopamine agonists had nearly four times the odds of experiencing excessive daytime sleepiness compared to those who did not take them, after adjusting for other variables. Standard levodopa therapy and MAO inhibitors did not show this association. The researchers note that the individuals who completed both surveys tended to be slightly younger, had lived with the condition for less time, and reported higher baseline quality of life than those lost to follow-up. Because healthier participants were more likely to finish the five years, the actual progression across the broader community could be even more pronounced. Furthermore, since the research relied on detailed questionnaires rather than overnight clinical sleep studies, specific diagnoses represent screening markers rather than hospital-based sleep lab measurements. Even so, the clear separation between stable insomnia and rising dream disturbances offers a practical roadmap for everyday wellbeing. Sleeplessness and total hours in bed may have more to do with typical ageing, whereas sleep talking, active dreaming, and daytime sleepiness track more directly with neurological changes and medication side effects. Rather than treating night-time difficulties as one unchanging problem, addressing individual symptoms, screening for sleep apnoea, and reviewing medications can make a genuine difference to daytime energy and night-time rest.